Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2014-10-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2014.933808PMID 24965615
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

  2014cited by this paper
• Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy

  2014influential reference
• Evaluation of Aortic Calcification With Lanthanum Carbonate vs. Calcium‐Based Phosphate Binders in Maintenance Hemodialysis Patients With Type 2 Diabetes Mellitus: An Open‐Label Randomized Controlled Trial

  2014cited by this paper
• Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

  2014cited by this paper
• Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial.

  2013cited by this paper
• Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.

  2013influential reference
• [Pharmacological and clinical profile of bixalomer (Kiklin(®) capsules): a new therapeutic agent for hyperphosphatemia].

  2013influential reference
• The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study

  2013cited by this paper
• Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation.

  2013influential reference
• Ferric Citrate Hydrate, a New Phosphate Binder, Prevents the Complications of Secondary Hyperparathyroidism and Vascular Calcification

  2013cited by this paper
• Long‐Term Treatment of Hyperphosphatemia With Bixalomer in Japanese Hemodialysis Patients

  2013cited by this paper
• Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.

  2013cited by this paper
• Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis

  2013cited by this paper
• Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.

  2013influential reference
• Use of phosphate-binding agents is associated with a lower risk of mortality.

  2013cited by this paper
• Pulmonary , gastrointestinal and urogenital pharmacology Effect of fatty acids on the phosphate binding of TRK-390 , a novel , highly selective phosphate-binding polymer

  2013cited by this paper
• Effect of Salivary Phosphate-Binding Chewing Gum on Serum Phosphate in Chronic Kidney Disease

  2013cited by this paper
• Use of phosphate binders in chronic kidney disease

  2013influential reference
• 新規高リン血症治療薬ビキサロマー（キックリン®カプセル）の薬理学的特性および臨床試験成績

  2013cited by this paper
• [Hyperphosphatemia and cardiovascular diseases : impact of vascular calcification and endothelial dysfunction].

  2012cited by this paper
• Effect of Oral JTT-751 (Ferric Citrate) on Hyperphosphatemia in Hemodialysis Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

  2012cited by this paper
• Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.

  2012cited by this paper
• Phosphate additives in food--a health risk.

  2012cited by this paper
• Effects of phosphate binders in moderate CKD.

  2012cited by this paper
• Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.

  2011cited by this paper
• Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction.

  2011cited by this paper
• Salivary glands: a new player in phosphorus metabolism.

  2011cited by this paper
• Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

  2011cited by this paper
• Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: A 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride

  2011cited by this paper
• Calcium and Phosphate: A Duet of Ions Playing for Bone Health

  2011cited by this paper
• Intestinal phosphate transport.

  2011influential reference
• Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.

  2011cited by this paper
• FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.

  2011cited by this paper
• Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?

  2011influential reference
• Chitosan iron(III) reduces phosphorus levels in alloxan diabetes-induced rats with signs of renal failure development.

  2010cited by this paper
• Efficacy and safety of SBR759, a new iron-based phosphate binder.

  2010cited by this paper
• A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.

  2010cited by this paper
• Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.

  2010cited by this paper
• PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease.

  2010cited by this paper
• Phosphate homeostasis and the renal-gastrointestinal axis.

  2010cited by this paper
• Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease.

  2010cited by this paper
• FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.

  2010cited by this paper
• Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

  2010cited by this paper
• Serum phosphate and mortality in patients with chronic kidney disease.

  2010cited by this paper
• Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.

  2009cited by this paper
• Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia.

  2009cited by this paper
• [Roles of hyperphosphatemia in vascular calcification].

  2009cited by this paper
• The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients

  2009cited by this paper
• Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.

  2009cited by this paper
• KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

  2009cited by this paper
• Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD)

  2009cited by this paper
• A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.

  2008cited by this paper
• Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.

  2007cited by this paper
• Emerging drugs for hyperphosphatemia

  2007cited by this paper
• Incident reporting and patient safety

  2007cited by this paper
• National Kidney Foundation K-DOQI: Clinical practice guidelines for bone metabolism and disease in chronic kidney disease

  2007cited by this paper
• A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate*

  2007cited by this paper
• Role of Phosphorus and Vitamin D Analogs in the Pathogenesis of Vascular Calcification

  2006cited by this paper
• Chronic kidney disease and mortality risk: a systematic review.

  2006cited by this paper
• The phosphatonins and the regulation of phosphate homeostasis.

  2006cited by this paper
• Sevelamer worsens metabolic acidosis in hemodialysis patients.

  2006cited by this paper
• Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.

  2006cited by this paper
• Sevelamer Hydrochloride and Calcium Bicarbonate Reduce Serum Fibroblast Growth Factor 23 Levels in Dialysis Patients

  2005cited by this paper
• Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure.

  2005influential reference
• Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial.

  2005cited by this paper
• Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study.

  2005cited by this paper
• Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

  2004cited by this paper
• Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

  2004cited by this paper
• K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

  2003cited by this paper
• Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.

  2003cited by this paper
• Cross-linking chitosan-Fe(III), an oral phosphate binder: studies in vitro and in vivo.

  2001cited by this paper
• Effect of Iron(III) Chitosan Intake on the Reduction of Serum Phosphorus in Rats

  2000cited by this paper
• Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients.

  1999cited by this paper
• New phosphate binding agents: ferric compounds.

  1999cited by this paper
• Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine.

  1999influential reference
• Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats.

  1999cited by this paper
• Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.

  1998cited by this paper
• Cross-linked iron dextran is an efficient oral phosphate binder in the rat.

  1996cited by this paper

• Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease

  2020cites this paper
• Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.

  2017cites this paper
• Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide

  2016cites this paper
• Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification

  2016influential citation
• Novel iron-containing phosphate binders for treatment of hyperphosphatemia

  2015cites this paper
• The future of phosphate binders: a perspective on novel therapeutics

  2014influential citation